Gastrointestinal Complications in Heart Transplant Patients: MITOS Study

详细信息	查看全文 | 推荐本文 |

• 作者：B. DÍ ; az ; F. Gonzá ; lez Vilchez ; L. Almenar ; J.F. Delgado ; N. Manito ; M.J. Paniagua ; M.G. Crespo ; E. Kaplinsky ; D.A. Pascual ; J. Ferná ; ndez-Yá ; ñ ; ez ; S. Mirabet ; J. Palomo
• 关键词：Blood transfusion ; Evaluation of the professional practices ; Continuous medical training
• 刊名：Transplantation Proceedings
• 出版年：2007
• 期刊代码：252_00411345
• 类别：med
• 出版时间：September 2007
• 卷：39
• 期：7
• 页码：2397-2400
• 文件大小：66 K

摘要

The most frequent immunosuppressive treatment complications in solid organ transplant recipients are gastrointestinal (GI) disorders.

Materials and Methods

An observational, cross-sectional study to evaluate the prevalence and management of GI complications in transplanted patients was conducted via a written questionnaire given to doctors at their practice.

Results

This study included 1788 patients; 181 corresponded to heart transplant recipients. The mean age for the heart transplant patients was 58.7 ± 11.8 years. The mean time from the transplantation was 5.2 ± 4.4 years. GI complications were seen in 38.7%of cases. Regarding the clinical management, in 72.9%of cases patients with GI complications received pharmacologic treatment, 86.3%with gastric protectors, 32.8%reduced the dose of some drug, 8.1%interrupted the drug temporarily, and 10.9%discontinued the drug permanently. The drug that was always discontinued was mycophenolate mofetil (MMF), and in 85.7%of cases in which the dose of an immunosuppressive drug was reduced, the reduced drug was also MMF.

Conclusions

Almost 40%of heart transplant recipients suffered GI complications which affected daily activities in most cases. The most used strategy to manage these complications was based on a treatment with gastric protectors together with dose reduction and/or partial or definitive MMF discontinuation.